                         SEQUENCE LISTING

<110>  Merck Sharp & Dohme Corp.
       MSD International GmbH (Singapore Branch)
       Agency For Science, Technology And Research
       Aronica, Pietro
       Brown, Christopher J
       Ferrer, Fernando J
       Johannes, Charles W
       Kannan, Srinivasaraghavan
       Lane, David P
       Partridge, Anthony W
       Sawyer, Tomi K
       Tan, Yaw Sing
       Verma, Chandra S
       Yuen, Tsz Ying
 
<120>  P53 ACTIVATOR PEPTIDOMIMETIC MACROCYCLES

<130>  24732

<150>  62/864531
<151>  2019-06-21

<160>  24    

<170>  PatentIn version 3.5

<210>  1
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D-DPMI-delta


<220>
<221>  MISC_FEATURE
<222>  (1)..(12)
<223>  Xaa1-Xaa12 all alpha-amino acids thereof have a D configuration

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is 6-F-Trp

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is p-CF3-Phe

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa12 optionally has a C-terminal amide

<400>  1

Thr Ala Xaa Tyr Ala Asn Xaa Glu Lys Leu Leu Arg 
1               5                   10          


<210>  2
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D-PMI-delta(1-5)


<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Xaa1 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  MISC_FEATURE
<222>  (1)..(12)
<223>  Xaa1-Xaa12 all alpha-amino acids thereof have a D configuration

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa1 optionally has a N-terminal acyl

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is 6-F-Trp

<220>
<221>  VARIANT
<222>  (5)..(5)
<223>  Xaa5 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is p-CF3-Phe

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa12 optionally has a C-terminal amide

<400>  2

Xaa Ala Xaa Tyr Xaa Asn Xaa Glu Lys Leu Leu Arg 
1               5                   10          


<210>  3
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D-PMI-delta(2-6)


<220>
<221>  MISC_FEATURE
<222>  (1)..(12)
<223>  Xaa1-Xaa12 all alpha-amino acids thereof have a D configuration

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa1 optionally has a N-terminal acyl

<220>
<221>  VARIANT
<222>  (2)..(2)
<223>  Xaa2 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is 6-F-Trp

<220>
<221>  VARIANT
<222>  (6)..(6)
<223>  Xaa6 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is p-CF3-Phe

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa12 optionally has a C-terminal amide

<400>  3

Thr Xaa Xaa Tyr Ala Xaa Xaa Glu Lys Leu Leu Arg 
1               5                   10          


<210>  4
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D-PMI-delta(2-9)


<220>
<221>  MISC_FEATURE
<222>  (1)..(12)
<223>  Xaa1-Xaa12 all alpha-amino acids thereof have a D configuration

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa1 optionally has a N-terminal acyl

<220>
<221>  VARIANT
<222>  (2)..(2)
<223>  Xaa2 is (S)-2-(7'-octenyl)-alanine

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is 6-F-Trp

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is p-CF3-Phe

<220>
<221>  VARIANT
<222>  (9)..(9)
<223>  Xaa9 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa12 optionally has a C-terminal amide

<400>  4

Thr Xaa Xaa Tyr Ala Asn Xaa Glu Xaa Leu Leu Arg 
1               5                   10          


<210>  5
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D-PMI-delta(5-9)


<220>
<221>  MISC_FEATURE
<222>  (1)..(12)
<223>  Xaa1-Xaa12 all alpha-amino acids thereof have a D configuration

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa1 optionally has a N-terminal acyl

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is 6-F-Trp

<220>
<221>  VARIANT
<222>  (5)..(5)
<223>  Xaa5 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is p-CF3-Phe

<220>
<221>  VARIANT
<222>  (9)..(9)
<223>  Xaa9 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa12 optionally has a C-terminal amide

<400>  5

Thr Ala Xaa Tyr Xaa Asn Xaa Glu Xaa Leu Leu Arg 
1               5                   10          


<210>  6
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D-PMI-delta(5-12)


<220>
<221>  MISC_FEATURE
<222>  (1)..(12)
<223>  Xaa1-Xaa12 all alpha-amino acids thereof have a D configuration

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa1 optionally has a N-terminal acyl

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is 6-F-Trp

<220>
<221>  VARIANT
<222>  (5)..(5)
<223>  Xaa5 is (S)-2-(7'-octenyl)-alanine

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is p-CF3-Phe

<220>
<221>  VARIANT
<222>  (12)..(12)
<223>  Xaa12 is (R)-2-(4'-pentenyl)-alanine

<400>  6

Thr Ala Xaa Tyr Xaa Asn Xaa Glu Lys Leu Leu Xaa 
1               5                   10          


<210>  7
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D-PMI-delta(6-10)


<220>
<221>  MISC_FEATURE
<222>  (1)..(12)
<223>  Xaa1-Xaa12 all alpha-amino acids thereof have a D configuration

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa1 optionally has a N-terminal acyl

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is 6-F-Trp

<220>
<221>  VARIANT
<222>  (6)..(6)
<223>  Xaa6 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is p-CF3-Phe

<220>
<221>  VARIANT
<222>  (10)..(10)
<223>  Xaa10 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa12 optionally has a C-terminal amide

<400>  7

Thr Ala Xaa Tyr Ala Xaa Xaa Glu Lys Xaa Leu Arg 
1               5                   10          


<210>  8
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D-PMI-delta(1,5,12)


<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Xaa1 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  MISC_FEATURE
<222>  (1)..(12)
<223>  Xaa1-Xaa12 all alpha-amino acids thereof have a D configuration

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa1 optionally has a N-terminal acyl

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is 6-F-Trp

<220>
<221>  VARIANT
<222>  (5)..(5)
<223>  Xaa5 is 2,2-(4'-penenyl)-glycine

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is p-CF3-Phe

<220>
<221>  VARIANT
<222>  (12)..(12)
<223>  Xaa12 is (R)-2-(7'-octenyl)-alanine

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa12 optionally has a C-terminal amide

<400>  8

Xaa Ala Xaa Tyr Xaa Asn Xaa Glu Lys Leu Leu Xaa 
1               5                   10          


<210>  9
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D-PMI-delta(1-5, 9-12)


<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Xaa1 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  MISC_FEATURE
<222>  (1)..(12)
<223>  Xaa1-Xaa12 all alpha-amino acids thereof have a D configuration

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa1 optionally has a N-terminal acyl

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is 6-F-Trp

<220>
<221>  VARIANT
<222>  (5)..(5)
<223>  Xaa5 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is p-CF3-Phe

<220>
<221>  VARIANT
<222>  (9)..(9)
<223>  Xaa9 is (S)-2-(4'-pentenyl)-alanine

<220>
<221>  VARIANT
<222>  (12)..(12)
<223>  Xaa12 is (R)-2-(7'-octenyl)-alanine

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa12 optionally has a C-terminal amide

<400>  9

Xaa Ala Xaa Tyr Xaa Asn Xaa Glu Xaa Leu Leu Xaa 
1               5                   10          


<210>  10
<211>  125
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  N-terminal domain of MDM2


<220>
<221>  MISC_FEATURE
<222>  (1)..(125)

<400>  10

Met Cys Asn Thr Asn Met Ser Val Pro Thr Asp Gly Ala Val Thr Thr 
1               5                   10                  15      


Ser Gln Ile Pro Ala Ser Glu Gln Glu Thr Leu Val Arg Pro Lys Pro 
            20                  25                  30          


Leu Leu Leu Lys Leu Leu Lys Ser Val Gly Ala Gln Lys Asp Thr Tyr 
        35                  40                  45              


Thr Met Lys Glu Val Leu Phe Tyr Leu Gly Gln Tyr Ile Met Thr Lys 
    50                  55                  60                  


Arg Leu Tyr Asp Glu Lys Gln Gln His Ile Val Tyr Cys Ser Asn Asp 
65                  70                  75                  80  


Leu Leu Gly Asp Leu Phe Gly Val Pro Ser Phe Ser Val Lys Glu His 
                85                  90                  95      


Arg Lys Ile Tyr Thr Met Ile Tyr Arg Asn Leu Val Val Val Asn Gln 
            100                 105                 110         


Gln Glu Ser Ser Asp Ser Gly Thr Ser Val Ser Glu Asn 
        115                 120                 125 


<210>  11
<211>  125
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  N-terminal domain of MDM4 (MDMX)


<220>
<221>  MISC_FEATURE
<222>  (1)..(125)

<400>  11

Met Thr Ser Phe Ser Thr Ser Ala Gln Cys Ser Thr Ser Asp Ser Ala 
1               5                   10                  15      


Cys Arg Ile Ser Pro Gly Gln Ile Asn Gln Val Arg Pro Lys Leu Pro 
            20                  25                  30          


Leu Leu Lys Ile Leu His Ala Ala Gly Ala Gln Gly Glu Met Phe Thr 
        35                  40                  45              


Val Lys Glu Val Met His Tyr Leu Gly Gln Tyr Ile Met Val Lys Gln 
    50                  55                  60                  


Leu Tyr Asp Gln Gln Glu Gln His Met Val Tyr Cys Gly Gly Asp Leu 
65                  70                  75                  80  


Leu Gly Glu Leu Leu Gly Arg Gln Ser Phe Ser Val Lys Asp Pro Ser 
                85                  90                  95      


Pro Leu Tyr Asp Met Leu Arg Lys Asn Leu Val Thr Leu Ala Thr Ala 
            100                 105                 110         


Thr Thr Asp Ala Ala Gln Thr Leu Ala Leu Ala Gln Asp 
        115                 120                 125 


<210>  12
<211>  379
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human MDM2 1-125 sequence


<220>
<221>  MISC_FEATURE
<222>  (1)..(379)
<223>  All alpha-amino acids have an L configuration

<400>  12

Met Ser Asp Lys Ile Ile His Ser Pro Ile Leu Gly Tyr Trp Lys Ile 
1               5                   10                  15      


Lys Gly Leu Val Gln Pro Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu 
            20                  25                  30          


Lys Tyr Glu Glu His Leu Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg 
        35                  40                  45              


Asn Lys Lys Phe Glu Leu Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr 
    50                  55                  60                  


Ile Asp Gly Asp Val Lys Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr 
65                  70                  75                  80  


Ile Ala Asp Lys His Asn Met Leu Gly Gly Cys Pro Lys Glu Arg Ala 
                85                  90                  95      


Glu Ile Ser Met Leu Glu Gly Ala Val Leu Asp Ile Arg Tyr Gly Val 
            100                 105                 110         


Ser Arg Ile Ala Tyr Ser Lys Asp Phe Glu Thr Leu Lys Val Asp Phe 
        115                 120                 125             


Leu Ser Lys Leu Pro Glu Met Leu Lys Met Phe Glu Asp Arg Leu Cys 
    130                 135                 140                 


His Lys Thr Tyr Leu Asn Gly Asp His Val Thr His Pro Asp Phe Met 
145                 150                 155                 160 


Leu Tyr Asp Ala Leu Asp Val Val Leu Tyr Met Asp Pro Met Cys Leu 
                165                 170                 175     


Asp Ala Phe Pro Lys Leu Val Cys Phe Lys Lys Arg Ile Glu Ala Ile 
            180                 185                 190         


Pro Gln Ile Asp Lys Tyr Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro 
        195                 200                 205             


Leu Gln Gly Trp Gln Ala Thr Phe Gly Gly Gly Asp His Pro Pro Lys 
    210                 215                 220                 


Leu Glu Val Leu Phe Gln Gly His Met His His His His His His Ser 
225                 230                 235                 240 


Ser Gly Val Asp Leu Gly Thr Glu Asn Leu Tyr Phe Gln Gly Met Cys 
                245                 250                 255     


Asn Thr Asn Met Ser Val Pro Thr Asp Gly Ala Val Thr Thr Ser Gln 
            260                 265                 270         


Ile Pro Ala Ser Glu Gln Glu Thr Leu Val Arg Pro Lys Pro Leu Leu 
        275                 280                 285             


Leu Lys Leu Leu Lys Ser Val Gly Ala Gln Lys Asp Thr Tyr Thr Met 
    290                 295                 300                 


Lys Glu Val Leu Phe Tyr Leu Gly Gln Tyr Ile Met Thr Lys Arg Leu 
305                 310                 315                 320 


Tyr Asp Glu Lys Gln Gln His Ile Val Tyr Cys Ser Asn Asp Leu Leu 
                325                 330                 335     


Gly Asp Leu Phe Gly Val Pro Ser Phe Ser Val Lys Glu His Arg Lys 
            340                 345                 350         


Ile Tyr Thr Met Ile Tyr Arg Asn Leu Val Val Val Asn Gln Gln Glu 
        355                 360                 365             


Ser Ser Asp Ser Gly Thr Ser Val Ser Glu Asn 
    370                 375                 


<210>  13
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TV cleavage site


<220>
<221>  MISC_FEATURE
<222>  (1)..(7)
<223>  All alpha-amino acids have an L configuration

<400>  13

Glu Asn Leu Tyr Phe Gln Ser 
1               5           


<210>  14
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  TV cleavage site with S7G substitution


<220>
<221>  MISC_FEATURE
<222>  (1)..(7)
<223>  All alpha-amino acids have an L configuration

<400>  14

Glu Asn Leu Tyr Phe Gln Gly 
1               5           


<210>  15
<211>  393
<212>  PRT
<213>  Homo spaiens


<220>
<221>  MISC_FEATURE
<222>  (1)..(393)
<223>  All alpha-amino acids have an L configuration

<400>  15

Met Glu Glu Pro Gln Ser Asp Pro Ser Val Glu Pro Pro Leu Ser Gln 
1               5                   10                  15      


Glu Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro Glu Asn Asn Val Leu 
            20                  25                  30          


Ser Pro Leu Pro Ser Gln Ala Met Asp Asp Leu Met Leu Ser Pro Asp 
        35                  40                  45              


Asp Ile Glu Gln Trp Phe Thr Glu Asp Pro Gly Pro Asp Glu Ala Pro 
    50                  55                  60                  


Arg Met Pro Glu Ala Ala Pro Arg Val Ala Pro Ala Pro Ala Ala Pro 
65                  70                  75                  80  


Thr Pro Ala Ala Pro Ala Pro Ala Pro Ser Trp Pro Leu Ser Ser Ser 
                85                  90                  95      


Val Pro Ser Gln Lys Thr Tyr Gln Gly Ser Tyr Gly Phe Arg Leu Gly 
            100                 105                 110         


Phe Leu His Ser Gly Thr Ala Lys Ser Val Thr Cys Thr Tyr Ser Pro 
        115                 120                 125             


Ala Leu Asn Lys Met Phe Cys Gln Leu Ala Lys Thr Cys Pro Val Gln 
    130                 135                 140                 


Leu Trp Val Asp Ser Thr Pro Pro Pro Gly Thr Arg Val Arg Ala Met 
145                 150                 155                 160 


Ala Ile Tyr Lys Gln Ser Gln His Met Thr Glu Val Val Arg Arg Cys 
                165                 170                 175     


Pro His His Glu Arg Cys Ser Asp Ser Asp Gly Leu Ala Pro Pro Gln 
            180                 185                 190         


His Leu Ile Arg Val Glu Gly Asn Leu Arg Val Glu Tyr Leu Asp Asp 
        195                 200                 205             


Arg Asn Thr Phe Arg His Ser Val Val Val Pro Tyr Glu Pro Pro Glu 
    210                 215                 220                 


Val Gly Ser Asp Cys Thr Thr Ile His Tyr Asn Tyr Met Cys Asn Ser 
225                 230                 235                 240 


Ser Cys Met Gly Gly Met Asn Arg Arg Pro Ile Leu Thr Ile Ile Thr 
                245                 250                 255     


Leu Glu Asp Ser Ser Gly Asn Leu Leu Gly Arg Asn Ser Phe Glu Val 
            260                 265                 270         


His Val Cys Ala Cys Pro Gly Arg Asp Arg Arg Thr Glu Glu Glu Asn 
        275                 280                 285             


Leu Arg Lys Lys Gly Glu Pro His His Glu Leu Pro Pro Gly Ser Thr 
    290                 295                 300                 


Lys Arg Ala Leu Ser Asn Asn Thr Ser Ser Ser Pro Gln Pro Lys Lys 
305                 310                 315                 320 


Lys Pro Leu Asp Gly Glu Tyr Phe Thr Leu Gln Ile Arg Gly Arg Glu 
                325                 330                 335     


Arg Phe Glu Met Phe Arg Glu Leu Asn Glu Ala Leu Glu Leu Lys Asp 
            340                 345                 350         


Ala Gln Ala Gly Lys Glu Pro Gly Gly Ser Arg Ala His Ser Ser His 
        355                 360                 365             


Leu Lys Ser Lys Lys Gly Gln Ser Thr Ser Arg His Lys Lys Leu Met 
    370                 375                 380                 


Phe Lys Thr Glu Gly Pro Asp Ser Asp 
385                 390             


<210>  16
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D-PMI-delta variant


<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Xaa1 is an alpha-amino or an alpha,alpha-disubstituted amino acid

<220>
<221>  MISC_FEATURE
<222>  (1)..(12)
<223>  Xaa1-Xaa12 all alpha-amino acids thereof have a D configuration

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa1 optionally has a N-terminal acyl

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is 6-F-Trp

<220>
<221>  VARIANT
<222>  (5)..(5)
<223>  Xaa5 is an alpha-amino or an alpha,alpha-disubstituted amino acid

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is p-CF3-Phe

<220>
<221>  VARIANT
<222>  (9)..(9)
<223>  Xaa9 is an alpha-amino or an alpha,alpha-disubstituted amino acid

<220>
<221>  VARIANT
<222>  (12)..(12)
<223>  Xaa12 is an alpha-amino or an alpha,alpha-disubstituted amino 
       acid

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa12 optionally has a C-terminal amide

<400>  16

Xaa Ala Xaa Tyr Xaa Asn Xaa Glu Xaa Leu Leu Xaa 
1               5                   10          


<210>  17
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D-PMI-delta(1-5)


<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Xaa1 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  MISC_FEATURE
<222>  (1)..(12)
<223>  Xaa1-Xaa12 all alpha-amino acids thereof have a D configuration

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is 6-F-Trp

<220>
<221>  VARIANT
<222>  (5)..(5)
<223>  Xaa5 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is p-CF3-Phe

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa12 has a C-terminal amide

<400>  17

Xaa Ala Xaa Tyr Xaa Asn Xaa Glu Lys Leu Leu Arg 
1               5                   10          


<210>  18
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D-PMI-delta(2-6)


<220>
<221>  MISC_FEATURE
<222>  (1)..(12)
<223>  Xaa1-Xaa12 all alpha-amino acids thereof have a D configuration

<220>
<221>  VARIANT
<222>  (2)..(2)
<223>  Xaa2 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is 6-F-Trp

<220>
<221>  VARIANT
<222>  (6)..(6)
<223>  Xaa6 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is p-CF3-Phe

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa12 has a C-terminal amide

<400>  18

Thr Xaa Xaa Tyr Ala Xaa Xaa Glu Lys Leu Leu Arg 
1               5                   10          


<210>  19
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D-PMI-delta(2-9)


<220>
<221>  MISC_FEATURE
<222>  (1)..(12)
<223>  Xaa1-Xaa12 all alpha-amino acids thereof have a D configuration

<220>
<221>  VARIANT
<222>  (2)..(2)
<223>  Xaa2 is (S)-2-(7'-octenyl)-alanine

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is 6-F-Trp

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is p-CF3-Phe

<220>
<221>  VARIANT
<222>  (9)..(9)
<223>  Xaa9 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa12 has a C-terminal amide

<400>  19

Thr Xaa Xaa Tyr Ala Asn Xaa Glu Xaa Leu Leu Arg 
1               5                   10          


<210>  20
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D-PMI-delta(5-9)


<220>
<221>  MISC_FEATURE
<222>  (1)..(12)
<223>  Xaa1-Xaa12 all alpha-amino acids thereof have a D configuration

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is 6-F-Trp

<220>
<221>  VARIANT
<222>  (5)..(5)
<223>  Xaa5 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is p-CF3-Phe

<220>
<221>  VARIANT
<222>  (9)..(9)
<223>  Xaa9 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa12 has a C-terminal amide

<400>  20

Thr Ala Xaa Tyr Xaa Asn Xaa Glu Xaa Leu Leu Arg 
1               5                   10          


<210>  21
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D-PMI-delta(5-12)


<220>
<221>  MISC_FEATURE
<222>  (1)..(12)
<223>  Xaa1-Xaa12 all alpha-amino acids thereof have a D configuration

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is 6-F-Trp

<220>
<221>  VARIANT
<222>  (5)..(5)
<223>  Xaa5 is (S)-2-(7'-octenyl)-alanine

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is p-CF3-Phe

<220>
<221>  VARIANT
<222>  (12)..(12)
<223>  Xaa12 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa12 has a C-terminal amide

<400>  21

Thr Ala Xaa Tyr Xaa Asn Xaa Glu Lys Leu Leu Xaa 
1               5                   10          


<210>  22
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D-PMI-delta(6-10)


<220>
<221>  MISC_FEATURE
<222>  (1)..(12)
<223>  Xaa1-Xaa12 all alpha-amino acids thereof have a D configuration

<220>
<221>  MISC_FEATURE
<222>  (1)..(12)
<223>  Xaa12 has a C-terminal amide

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is 6-F-Trp

<220>
<221>  VARIANT
<222>  (6)..(6)
<223>  Xaa6 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is p-CF3-Phe

<220>
<221>  VARIANT
<222>  (10)..(10)
<223>  Xaa10 is (R)-2-(4'-pentenyl)-alanine

<400>  22

Thr Ala Xaa Tyr Ala Xaa Xaa Glu Lys Xaa Leu Arg 
1               5                   10          


<210>  23
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D-PMI-delta(1,5,12)


<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Xaa1 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is 6-F-Trp

<220>
<221>  VARIANT
<222>  (5)..(5)
<223>  Xaa5 is 2,2-(4'-penenyl)-glycine

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is p-CF3-Phe

<220>
<221>  VARIANT
<222>  (12)..(12)
<223>  Xaa12 is (R)-2-(7'-octenyl)-alanine

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa1-Xaa12 all alpha-amino acids thereof have a D configuration

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa12 has a C-terminal amide

<400>  23

Xaa Ala Xaa Tyr Xaa Asn Xaa Glu Lys Leu Leu Xaa 
1               5                   10          


<210>  24
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D-PMI-delta(1-5, 9-12)


<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Xaa1 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  MISC_FEATURE
<222>  (1)..(12)
<223>  Xaa1-Xaa12 all alpha-amino acids thereof have a D configuration

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is 6-F-Trp

<220>
<221>  VARIANT
<222>  (5)..(5)
<223>  Xaa5 is (R)-2-(4'-pentenyl)-alanine

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is p-CF3-Phe

<220>
<221>  VARIANT
<222>  (9)..(9)
<223>  Xaa9 is (S)-2-(4'-pentenyl)-alanine

<220>
<221>  VARIANT
<222>  (12)..(12)
<223>  Xaa12 is (R)-2-(7'-octenyl)-alanine

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa12 has a C-terminal amide

<400>  24

Xaa Ala Xaa Tyr Xaa Asn Xaa Glu Xaa Leu Leu Xaa 
1               5                   10          


